Exai Bio Appoints Dave Daly as Chief Executive Officer
Exai to accelerate product development and partnering of its novel oncRNA- and generative AI-based liquid biopsy platform Dave Daly brings more than 30 years of extensive cancer diagnostics and executive leadership experience PALO ALTO, Calif. – Exai Bio, a next-generation oncRNA- and generative AI-based liquid biopsy company, today announced the appointment of Dave Daly as Chief Executive Officer. With more than 30 years of cancer … Continue reading Exai Bio Appoints Dave Daly as Chief Executive Officer